Danaher Corp
Exchange: NYSESector: HealthcareIndustry: Diagnostics & Research
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com. © 2025 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. 2025-14761 SOURCE Beckman Coulter Diagnostics
Did you know?
Price sits at 26% of its 52-week range.
Current Price
$191.12
+0.17%GoodMoat Value
$93.20
51.2% overvaluedProfile
Valuation (TTM)
Market Cap$135.00B
P/E37.35
EV$148.01B
P/B2.57
Shares Out706.35M
P/Sales5.49
Revenue$24.57B
EV/EBITDA21.38
Danaher Corp (DHR) Stock Analysis
GoodMoat Analysis
Danaher is a high-quality life sciences and diagnostics conglomerate with a strong competitive moat, but it appears significantly overvalued based on the provided GoodMoat target price. A value investor would find the business model attractive but the current price unfavourable.
Read full analysis
Danaher Corp operates a portfolio of businesses in life sciences, diagnostics, and environmental & applied solutions, structured around its proprietary Danaher Business System (DBS) for continuous improvement. Applying the GoodMoat framework, the company likely scores highly on Moat Identification, particularly in Switching Costs (mission-critical instruments and consumables), Niche Dominance in specific diagnostic segments, and a culture of operational excellence embedded through DBS. Its history as a successful serial acquirer also suggests strengths in Founder-Led Execution and strategic capital allocation. This indicates a durable competitive advantage, likely passing the initial Moat & Quality Gate. However, the valuation assessment presents a major hurdle. The stock trades at a P/E of 36.6x and a price of $187.15, which is more than double the provided GoodMoat Target of $93.20. This implies a negative margin of safety of over 50%, placing it firmly in the 'Unfavourable' band per the framework's DCF guidelines. While the business exhibits quality traits like a solid operating margin of 19.1% and moderate debt, its current growth (4.6% YoY revenue growth) and returns (6.9% ROE) do not justify such a premium multiple. Per the Decision Framework, a stock with a strong moat but severe overvaluation and a negative margin of safety falls into the 'Unfavourable' category for a value investor at this price. Analysis based on data as of 2024-05-15.
Market Cap$135.00B
Current Price$191.12
P/E Ratio37.35
Forward P/E—
PEG Ratio2.95
EPS$5.05
Book Value$74.37
P/B Ratio2.57
DHR Financial Charts
FCF vs CAPEX
FCFCAPEX
Forward estimates use 8.0% FCF growth (CAGR)
Cash vs Debt
Net Debt: 13.8B
Revenue
17.9B
FY19
22.3B
FY20
24.8B
FY21
26.6B
FY22
23.9B
FY23
23.9B
FY24
24.6B
FY25
Net Income
3.0B
FY19
3.6B
FY20
6.4B
FY21
7.2B
FY22
4.8B
FY23
3.9B
FY24
3.6B
FY25
DHR 52-Week Range
$173.43
$241.52
50-Day MA: $205.52200-Day MA: $209.00
Did you know?
Trading 51% above its estimated fair value of $93.20.
Danaher Corp (DHR) Financial Summary
Danaher Corp (DHR) is a Healthcare company in the Diagnostics & Research industry, listed on NYSE. The stock currently trades at $191.12 with a market capitalization of $135.00B.
Key valuation metrics include a P/E ratio of 37.35, price-to-book ratio of 2.57, and EPS of $5.05. The company reports a profit margin of 14.7% and return on equity of 6.9%.
DHR Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $135.00B |
| P/E Ratio | 37.35 |
| EPS | $5.05 |
| P/B Ratio | 2.57 |
| P/S Ratio | 5.49 |
| EV/EBITDA | 21.38 |
| Dividend Yield | 0.65% |
| Profit Margin | 14.7% |
| Return on Equity | 6.9% |
| Debt/Equity | 0.35 |
DHR Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $17.91B | $3.01B |
| FY20 | $22.28B | $3.65B |
| FY21 | $24.80B | $6.43B |
| FY22 | $26.64B | $7.21B |
| FY23 | $23.89B | $4.76B |
| FY24 | $23.88B | $3.90B |
| FY25 | $24.57B | $3.61B |
Danaher Corp (DHR) Valuation
Based on GoodMoat's DCF model, Danaher Corp has a fair value estimate of $93.20. At the current price of $191.12, the stock appears 105.1% overvalued relative to our intrinsic value estimate.
DHR Quality Indicators
Danaher Corp maintains a profit margin of 14.7% and an operating margin of 19.1%. Return on equity stands at 6.9%. The current ratio is 1.87. Debt-to-equity ratio is 0.35.
About Danaher Corp
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com. © 2025 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. 2025-14761 SOURCE Beckman Coulter Diagnostics
DHR Free Cash Flow
Danaher Corp generated $5.29B in trailing twelve-month free cash flow, representing an FCF yield of 3.92%. This moderate FCF yield indicates reasonable cash generation.
DHR Shares Outstanding
Danaher Corp has 0.71 billion shares outstanding at a share price of $191.12, giving it a market capitalization of $135.00B.
DHR Recent Insider Trades
Recent insider transactions at Danaher Corp include:
| Insider | Type | Shares | Value |
|---|---|---|---|
| Milosevich Gregory M (Executive Vice President) | SELL | 1,320 | $274574.52 |